Lysosomal Storage Disorders and Epilepsy

Lysosomal storage disorders are inherited metabolic diseases caused by dysfunction of the lysosomal system, leading to accumulation of substances that cells cannot process normally.

Some lysosomal disorders primarily affect other organs. Others involve the central nervous system and can cause developmental regression, movement disorders, visual loss, cognitive decline and epilepsy.

Why lysosomes matter in the brain

Lysosomes help cells break down and recycle proteins, lipids and other cellular material.

Neurons are particularly vulnerable when this system fails because they are long-lived cells that depend heavily on effective intracellular recycling.

Not every lysosomal disease causes epilepsy

There are more than 70 recognised lysosomal storage diseases, and their neurological involvement varies considerably.

Epilepsy is particularly important in neurodegenerative lysosomal disorders that affect cortical networks.

Neuronal ceroid lipofuscinoses

The neuronal ceroid lipofuscinoses (NCLs), often called Batten diseases, are among the clearest examples.

They are genetically diverse disorders characterised by progressive neurodegeneration, seizures, cognitive and motor decline and, in many forms, visual failure.

Some NCLs cause severe drug-resistant epilepsy.

CLN2 disease

CLN2 disease is caused by deficiency of tripeptidyl peptidase 1 (TPP1).

Children commonly develop seizures followed by progressive loss of language, motor and cognitive abilities.

Enzyme replacement therapy with cerliponase alfa can slow neurological decline in eligible patients but does not remove the need for seizure management.

GM1 and GM2 gangliosidoses

Gangliosidoses can produce progressive neurological deterioration, abnormal tone, movement disorders and seizures.

Examples include Tay–Sachs disease and Sandhoff disease.

Niemann–Pick disease type C

Niemann–Pick type C is a lysosomal lipid-trafficking disorder that can cause vertical gaze palsy, ataxia, dystonia, cognitive decline, psychiatric symptoms and seizures.

Age of onset is highly variable.

Gaucher disease

Most people with Gaucher disease do not have severe neurological involvement.

Neuropathic forms—types 2 and 3—can involve the brain and may include seizures in some patients.

Krabbe disease and metachromatic leukodystrophy

These are lysosomal leukodystrophies in which white-matter degeneration is prominent.

Seizures may occur as disease progresses, although epilepsy is only one part of a broader neurological syndrome.

Mucopolysaccharidoses

Some mucopolysaccharidoses involve the CNS and can be associated with seizures, hydrocephalus, cognitive impairment and progressive neurological disease.

The epilepsy phenotype varies greatly by subtype.

Why diagnosis can be delayed

Early symptoms may initially resemble isolated epilepsy, cerebral palsy, autism, developmental delay or another neurodegenerative disease.

Progressive loss of previously acquired skills is an important warning sign.

Clues that suggest a metabolic or lysosomal cause

Possible clues include developmental regression, progressive visual loss, movement disorder, organ enlargement, skeletal abnormalities, unusual MRI findings, unexplained ataxia, worsening cognition or a family history of similar disease.

Testing

Diagnosis may involve enzyme assays, biomarkers, genetic testing, metabolic studies and neuroimaging.

Increasingly, exome or genome sequencing identifies lysosomal disorders when the clinical presentation is not classic.

Epilepsy treatment

Antiseizure medicine is selected according to seizure type and the individual disorder.

Some lysosomal diseases produce multiple seizure types and progressive drug resistance.

Disease-modifying treatment

Depending on the disorder, treatment may include enzyme replacement, substrate reduction, haematopoietic stem-cell transplantation, chaperone therapy or emerging gene-based treatments.

Most lysosomal disorders still lack a therapy that fully reverses CNS disease.

Why early diagnosis matters

Some disease-modifying treatments work best before extensive irreversible neurological injury has occurred.

This is one reason progressive epilepsy plus regression should prompt investigation beyond seizure control alone.

The central point

Lysosomal storage disorders are not one epilepsy syndrome. They are a large group of inherited metabolic diseases in which epilepsy may be one manifestation of progressive neuronal or white-matter dysfunction.

Sources

Evidence checked: September 2026.